Victoria,' which came to Netflix in December 2025, stars Jenna Coleman as Queen Victoria and tells the story of her life.

Plus, what was really going on between Victoria and Lord Melbourne?

New Jersey Devils star Jack Hughes is being evaluated for a non-hockey injury on his hand, the team announced Friday. According to sources, Hughes injured his hand in a "freak accident" at a team ...

The former Manchester United and England defender Paul Parker was asked about his one-time team-mate Mark Hughes in the luxury of Tottenham Hotspur’s stadium on Saturday. “He was the last of my ...

When Coleman Hughes first opened a Thomas Sowell book, he wasn’t searching for an ideology — he was searching for clarity. At 19, adrift after dropping out of Juilliard and mourning the loss of his ...

As the 2025-26 coaching carousel moves with dizzying speed, a looming reality approaches teams who made head coaching changes like a hidden iceberg in the North Atlantic Ocean. The transfer portal is ...

BUCKSNORT, Tenn. (WKRN) — One family has officially filed suit following the Bucksnort explosion, following the loss of their loved one, 37-year-old Jeremy Moore. Moore is one of the 16 workers who ...

With 60 points in a charity basketball game and vows to make a second-year leap as an NFL receiver, Keon Coleman created a lot of noise in the offseason. He walked that talk in Week 1, with an ...

NEWARK, N.J.-- Luke Hughes had his mind set on securing a long-term contract with the New Jersey Devils, to remain in the place he already considers his home away from home. The 22-year-old defenseman ...

Oregon running back Makhi Hughes will redshirt the remainder of the 2025 season after playing a limited role for the No. 2 Ducks. Hughes didn't travel with Oregon to its highly anticipated showdown ...

The New Jersey Devils agreed to terms with young defenseman Luke Hughes on a seven-year contract worth $63 million. General manager Tom Fitzgerald announced the deal. Hughes will count $9 million ...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...